Sulforaphane Plus Fulvestrant: Research Summary for ER+ Breast Cancer
A review of the preclinical and clinical evidence — including the STEM trial — on combining sulforaphane (as SFX-01) with fulvestrant in ER-positive metastatic breast cancer.
Sulforaphane (SFN) — the isothiocyanate found in broccoli sprouts and cruciferous vegetables — and fulvestrant (Faslodex), a selective estrogen receptor degrader (SERD) used in ER-positive metastatic breast cancer, have been studied together in preclinical and early clinical settings, primarily using a stabilised, bioavailable form of sulforaphane called SFX-01. The combination targets endocrine-therapy resistance and cancer stem-like cell activity, with one Phase II trial (STEM) showing measurable, though modest, clinical benefit when SFX-01 was added to fulvestrant in patients already progressing on it.
How Fulvestrant Works
Fulvestrant is a complete estrogen receptor antagonist that binds ERα with high affinity, blocks receptor dimerization and both activation domains (AF-1 and AF-2), and accelerates ER protein degradation via the ubiquitin-proteasome pathway, fully shutting down estrogen-driven transcription. Unlike tamoxifen, which retains partial agonist activity, fulvestrant has no agonist effects, making it a preferred second-line endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer.
How Sulforaphane Interacts With ER Signaling
Independent of fulvestrant, sulforaphane itself downregulates ERα protein in MCF-7 breast cancer cells, partly by suppressing ERα transcription and partly by promoting proteasome-mediated ERα protein degradation — a mechanism that overlaps conceptually with fulvestrant's degrader action. Some studies find SFN reduces ERα mRNA only at higher concentrations (around 30 μM), while other formulations (R-sulforaphane) affect ERα transcript without changing protein levels, indicating dose- and isomer-dependent effects that are not fully consistent across studies. Sulforaphane is also reported to support estrogen detoxification by upregulating phase 2 detoxification enzymes.
The Key Combination Study: SFX-01 Plus Fulvestrant
The most direct evidence on this pairing comes from a 2020 Oncogene paper by Simões et al., which tested SFX-01 (a stabilised, more bioavailable sulforaphane formulation) combined with fulvestrant in ER+ patient-derived xenograft (PDX) models and patient samples.
Fulvestrant alone paradoxically increased mammosphere formation efficiency and aldehyde dehydrogenase (ALDH)-positive cancer stem-like cell activity in PDX tumors, a known driver of endocrine resistance.
Adding SFX-01 reversed this stem-cell enrichment and reduced tumor-initiating cell frequency in secondary transplants.
Mechanistically, fulvestrant (and tamoxifen) induced STAT3 phosphorylation in tumor cells; SFX-01 suppressed phospho-STAT3 and was shown to directly bind STAT3 in patient and PDX samples, inhibiting downstream stemness genes MUC1 and OSMR.
In the BB3RC31 PDX model, SFX-01 plus fulvestrant reduced spontaneous lung micrometastases by 50%, an effect not seen when SFX-01 was combined with tamoxifen in that same model, suggesting the fulvestrant pairing may be particularly effective at blocking metastatic colonization in sensitive tumors.
This work established a rationale: SFN/SFX-01 doesn't just add antiproliferative effects, it specifically counteracts a resistance mechanism (STAT3-driven stem-like cell expansion) that fulvestrant itself can inadvertently activate.
Clinical Trial Evidence: The STEM Trial
Based on this preclinical rationale, Evgen Pharma ran the STEM trial (NCT02970682), an open-label Phase II study adding SFX-01 (300 mg twice daily) to whichever endocrine therapy — aromatase inhibitor, tamoxifen, or fulvestrant — a patient's ER+/HER2- metastatic breast cancer had already progressed on.
Metric | Result |
|---|---|
Overall clinical benefit rate (CBR) at 24 weeks | ~24–26% (12/46 patients) |
Objective response rate | 4.3% (2/46 patients) |
CBR specifically with fulvestrant + SFX-01 | 1/7 patients (14%) |
CBR with tamoxifen + SFX-01 | 4/8 patients (50%) |
CBR with aromatase inhibitor + SFX-01 | 7/28 patients (25%) |
Median duration of clinical benefit | 9.0 months (range 5.9–17.0 months) |
Safety | Well tolerated; main side effects were indigestion (~25%) and nausea (~20%), no severe drug-related AEs |
Both primary endpoints (clinical benefit rate and safety/tolerability) were met across the trial as a whole. Notably, the fulvestrant-specific arm had the smallest sample size (n=7) and the lowest response rate of the three combinations, while tamoxifen and aromatase inhibitor arms performed better — meaning that although the fulvestrant pairing is mechanistically well-supported preclinically, the clinical signal for that specific combination was weaker than for the other endocrine partners in this small trial. Five patients overall stayed on SFX-01 combination therapy for over a year without progression, and the sponsor concluded that further development in metastatic breast cancer was warranted.
Just one MCS Formulas Broccoli Ultra, Sulforaphane capsule contains about 375mg of free & stabilised Sulforaphane, most supplements deliver the precursor of free Sulforaphane, called Sulforaphane Glucosinolate. Visit the our Trusted Suppliers and Disocunts page to learn more.
Broader Context: Sulforaphane's Anticancer Mechanisms
Beyond the fulvestrant-specific data, sulforaphane has wide-ranging anticancer activity relevant to breast cancer that likely underlies its synergy with endocrine therapy: it increases reactive oxygen species and oxidative stress selectively in cancer cells, promotes apoptosis, arrests cells at the G2/M checkpoint, inhibits histone deacetylases (HDACs), and modulates Nrf2 antioxidant signaling. It has also shown synergy with other chemotherapeutic and dietary agents (gemcitabine, paclitaxel, genistein, sodium butyrate), reinforcing its general role as a "sensitizer" that can enhance other treatments' effects while limiting resistance-related pathways.
Practical Takeaways and Limitations
Current evidence supports a specific, mechanistically grounded rationale for combining sulforaphane (as SFX-01) with fulvestrant — namely reversing fulvestrant-induced cancer stem cell activity via STAT3 inhibition — but clinical data remain limited to one small, open-label Phase II trial without a placebo comparator, and the fulvestrant subgroup was the smallest and weakest-responding arm. Standard dietary sulforaphane (e.g., from broccoli sprouts) has much lower and more variable bioavailability than the stabilised SFX-01 formulation used in these studies, so results from SFX-01 trials should not be assumed to directly translate to supplement use. No large randomized controlled trial has yet confirmed whether adding sulforaphane/SFX-01 to fulvestrant improves progression-free or overall survival compared with fulvestrant alone.